Chidozie Ugwumba

Neuberger Berman BD LLC is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. It is directly owned by Neuberger Berman Investment Advisers LLC, which is an indirect, wholly-owned subsidiary of Neuberger Berman Group LLC, which is owned by NBSH Acquisition LLC. The firm traces their origin back to the 1939 founding of Neuberger & Berman, its predecessor firm. In 1950, Neuberger Berman became one of the first firms to offer a no-load mutual fund to individual investors. Neuberger Berman BD manages a range of equity, fixed income, private equity and hedge fund strategies on behalf of institutions, advisors and individual investors worldwide.

Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT.

Stellular Bio, Inc. develops technology to produce independent human platelets from human induced pluripotent stem cells. The company was founded by Jonathan Thon, Joseph Italiano and Sven Karlsson in 2014 and is headquartered in Watertown, MA.

CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA.

Partners Group Inc. (United States) is a Private Equity/Venture Capital firm, a subsidiary of Partners Group (Private Equity) founded in 2000. The firm is headquartered in Houston.

Micronoma, Inc. is a cancer-detection company that uses signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma is headquartered in San Diego, CA. The company aims to revolutionize and advance the practice of early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients' needs are identified and addressed by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company was founded in 2019 by Sandrine Miller-Montgomery, Greg Poore, Rob Knight, and Magda Marquet. Sandrine Miller-Montgomery has been the CEO since 2019.